Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) have been given an average recommendation of “Moderate Buy” by the eight analysts that are presently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $45.8333.

A number of analysts have commented on the stock. Weiss Ratings lowered shares of Zai Lab from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 4th. Cantor Fitzgerald decreased their price target on shares of Zai Lab from $55.00 to $37.00 and set an “overweight” rating for the company in a research note on Friday, February 27th. JPMorgan Chase & Co. decreased their price target on shares of Zai Lab from $39.00 to $32.00 and set an “overweight” rating for the company in a research note on Wednesday, March 18th. Citigroup decreased their price target on shares of Zai Lab from $47.00 to $44.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Finally, Wall Street Zen lowered shares of Zai Lab from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th.

Zai Lab Price Performance

Shares of ZLAB stock opened at $18.18 on Monday. The company has a market cap of $2.06 billion, a price-to-earnings ratio of -11.22 and a beta of 0.78. Zai Lab has a 52 week low of $15.96 and a 52 week high of $41.20. The firm has a 50 day moving average of $19.72 and a 200-day moving average of $19.00.

Zai Lab (NASDAQ:ZLAB) last posted its quarterly earnings results on Wednesday, April 1st. The company reported ($0.50) earnings per share (EPS) for the quarter. The business had revenue of $99.61 million during the quarter. Zai Lab had a negative net margin of 39.29% and a negative return on equity of 24.32%. Analysts anticipate that Zai Lab will post -2.23 earnings per share for the current year.

Insider Activity

In other news, CEO Ying Du sold 50,000 shares of the company’s stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $20.09, for a total value of $1,004,500.00. Following the completion of the sale, the chief executive officer owned 1,122,626 shares in the company, valued at $22,553,556.34. This represents a 4.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Yajing Chen sold 5,199 shares of the company’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $20.39, for a total transaction of $106,007.61. Following the completion of the sale, the chief financial officer owned 32,558 shares of the company’s stock, valued at approximately $663,857.62. The trade was a 13.77% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 89,561 shares of company stock worth $1,811,705. 4.88% of the stock is owned by insiders.

Institutional Trading of Zai Lab

An institutional investor recently raised its position in Zai Lab stock. Royal Bank of Canada increased its stake in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 214.3% during the first quarter, according to its most recent filing with the SEC. The fund owned 13,771 shares of the company’s stock after buying an additional 9,390 shares during the quarter. Royal Bank of Canada’s holdings in Zai Lab were worth $498,000 at the end of the most recent quarter. Institutional investors own 41.65% of the company’s stock.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.